This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning.
View this resource Bookmark this resourceProof of Concept
Size of ERC Proof of Concept GrantsThe financial contribution will be awarded as a lump sum of EUR 150 000 for a period of 18 months. The ERC expects that normally proof of concept activities should be completed within 12 months. However, to allow for those projects that require more preparation time, the grant agreements will be signed for 18 months. Extensions of the duration of proof of concept projects may be granted only exceptionally.
The lump sum will cover the beneficiaries’ direct and indirect eligible costs for the project: if the project is implemented properly the amounts will be paid regardless of the costs actually incurred. The lump sum has been designed to cover the beneficiaries’ personnel costs, subcontracting, purchase costs, other cost categories and indirect costs.
View this resource Bookmark this resource